Boston Scientific (NYSE:BSX) Issues Q3 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its third quarter 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.800-0.820 for the period, compared to the consensus EPS estimate of 0.840. The company issued revenue guidance of $5.2 billion-$5.3 billion, compared to the consensus revenue estimate of $5.4 billion. Boston Scientific also updated its FY 2026 guidance to 3.280-3.320 EPS.

Boston Scientific Stock Down 0.3%

NYSE BSX opened at $45.92 on Friday. The company has a 50 day moving average of $46.35 and a 200-day moving average of $62.37. Boston Scientific has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market cap of $68.25 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.89 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts expect that Boston Scientific will post 3.31 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BSX shares. Evercore set a $65.00 price target on Boston Scientific in a report on Monday, July 6th. BTIG Research reduced their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. Citigroup reduced their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research report on Thursday. Mizuho cut their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Finally, TD Cowen dropped their price target on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 9,800 shares of company stock worth $554,012 in the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded second-quarter expectations, reporting adjusted EPS of $0.86 versus $0.83 expected and revenue of $5.44 billion versus approximately $5.38 billion expected. Revenue increased 7.5% year over year, supported by broad-based cardiovascular growth, international sales and margin expansion. Boston Scientific Q2 Earnings & Revenues Top Estimates
• Positive Sentiment: Management raised its full-year sales-growth outlook to roughly 5.5%–6.5%, while highlighting cost savings, new product launches and a multiyear restructuring plan intended to improve efficiency. The planned restructuring could ultimately generate about $500 million in savings. Boston Scientific Q2 Results, Recall and Restructuring Plan
• Positive Sentiment: Boston Scientific’s pending acquisition of Penumbra adds exposure to thrombectomy and embolization markets. Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with gross margin improving to 67.9%. Penumbra Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Despite lower targets, UBS, BTIG, TD Cowen and Truist maintained buy ratings. Their revised targets—$74, $60, $56 and $57, respectively—still imply substantial upside, but the reductions signal more cautious near-term expectations. BTIG Lowers Boston Scientific Price Target
• Negative Sentiment: Boston Scientific cut full-year adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the roughly $3.31 consensus midpoint, and set third-quarter EPS guidance at $0.80–$0.82. Softer demand for the WATCHMAN heart-implant portfolio and pressure in electrophysiology were the primary concerns. Boston Scientific Lowers Full-Year Guidance
• Negative Sentiment: The company also disclosed a recall involving its Rapid Refill Continuous Injection System and restructuring costs of up to $800 million. These charges weigh on earnings visibility even though management expects longer-term operating benefits. Boston Scientific Cuts Outlook Ahead of Restructuring

Institutional Investors Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently modified their holdings of BSX. Sunbelt Securities Inc. raised its holdings in Boston Scientific by 33.0% during the fourth quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider’s stock worth $135,000 after buying an additional 350 shares during the last quarter. Compound Planning Inc. lifted its position in Boston Scientific by 14.7% during the fourth quarter. Compound Planning Inc. now owns 15,423 shares of the medical equipment provider’s stock valued at $1,471,000 after purchasing an additional 1,978 shares during the period. Axxcess Wealth Management LLC grew its position in Boston Scientific by 130.9% in the 4th quarter. Axxcess Wealth Management LLC now owns 28,347 shares of the medical equipment provider’s stock worth $2,703,000 after purchasing an additional 16,068 shares during the period. Corient Private Wealth LLC raised its stake in Boston Scientific by 11.1% during the 4th quarter. Corient Private Wealth LLC now owns 242,992 shares of the medical equipment provider’s stock valued at $22,238,000 after buying an additional 24,194 shares during the last quarter. Finally, Strive Financial Group LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth $1,499,000. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.